Doctoral candidate @UniOfOxford UK Hodgkin Lymphoma group member @EHA_Hematology Lymphoma SWG member and CRTH 2025 scholar @tcddublin alumnus
Joined May 2021
- Tweets155
- Following132
- Followers312
- Likes896
Pinned Tweet
An award only possible by the superlative mentorship of @graham74GC and @Capt__Kirkwood , and the dedication of all of our amazing UK and international collaborators!
The incredible @ABarrettHaem receiving an abstract away at #ISHL14 for her work on older Hodgkin patients. Richly deserved. 👏👏👏
Aisling Barrett retweeted
#ISHL14 Abstract Awards recipients. It is all girl party this year! And for the reason. BIG congrats to new gen of scientits! Well deserved! Good choice! 🌹 @ABarrettHaem 👏
Aisling Barrett retweeted
The incredible @ABarrettHaem receiving an abstract away at #ISHL14 for her work on older Hodgkin patients. Richly deserved. 👏👏👏
Very nice to join my first @EORTC lymphoma group session as ECI- such a welcoming group with motivating discussions!
Now on to the wonderful ISHL meeting in sunny Cologne!
New paper alert 👀 thank you to @Haematologica for publishing our analysis of ~30,000 UK classic Hodgkin lymphoma patients, with a focus on the ever-interesting older population. NB: anthracycline is key! haematologica.org/article/vi… @DavidJCutter @graham74GC
Aisling Barrett retweeted
Ready to take your next step in clinical research? Applications for CRTH are now open.
The Clinical Research Training in Hematology (CRTH) program is a nine-month training and mentoring experience designed for early-career hematologists who want to grow as clinical researchers.
Successful applicants will be trained and coached by top-tier experts in their field, who will help you develop your knowledge and skills in clinical science through mentoring and training during two multi-day workshops and a session at the EHA Congress.
Learn more about CRTH and apply by September 15, 2026 (15:00 CEST): eha.fyi/CRTH_2027
Aisling Barrett retweeted
Great to see the EHA relapsed Hodgkin guidelines in print. Challenging to write these when access to targted therapies is so variable across Europe.
onlinelibrary.wiley.com/doi/…
Thanks Raúl! #CRTHmentor 😉
Wonderful to have the opportunity to present the exciting findings of the Avenue trial at EHA!
3 year OS 100% and PFS 91% with a sequential approach to upfront PD-L1 inhibition and RATHL approach in untreated advanced classic Hodgkin lymphoma
Many congratulations to @ABarrettHaem for delivering a fantastic presentation in the final data of the Avenue trial - avelumab prior to a RATHL approach in Hodgkin. #EHA2026
Aisling Barrett retweeted
‼️ #EHA2026 simultaneous publication by @mattwilson2287 et al:
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Analysis of 1,923 Patients
Read the full article: bit.ly/4efwgue
Aisling Barrett retweeted
#EHA2026 LBA
Primary results of BRUIN CLL322
FD Pirto-VenR vs VenR
80% cBTKi exposed
2Y PFS PVR 86.9% vs VR 71.8%
Subgroups of TP53 & PD on cBTKi marked ⬆️PFS
Substantial ⬆️ in PFS with little added tox.
Practice changing trial in R/R #CLL
#pirtobrutinib #BRUINCLL322 #EHA2026
Aisling Barrett retweeted
▶️▶️Great to see this out. #Pirtobrutinib is highly active in cBTKi exposed R/R WM. #WM #lymsm
Safety & activity of pirtobrutinib in pts with R/R WM: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial - Lancet Haematology thelancet.com/journals/lanha…
Aisling Barrett retweeted
A huge thank you to our incredible faculty who joined us in Lisbon for the Inaugural CLL & Lymphoma EU Focus Meeting 2026. 🇵🇹 We could not have asked for a better inaugural meeting.
@ABarrettHaem @HemostasisToday
Really enjoying this excellent meeting with world class speakers and talks!
Stephan Stilgenbauer, MD and Franck Morschhauser, MD have opened Day 1 of the inaugural CLL & Lymphoma EU Focus Meeting 2026 in Lisbon. 🇵🇹
Sign up to receive the meeting recordings: links.md-education.com/cll_e…
#MDEducation
Very proud of our group today and especially Andrew Challenger's work looking at excess mortality in DLBCL patients- which persists even beyond 10 years from diagnosis. Needs to be considered in our trial designs! @DavidJCutter @graham74GC
doi.org/10.1182/bloodadvance…
Thrilled for my CRTH mentor Raul, richly deserved!
Aisling Barrett retweeted
This week, our Clinical Research Training in Hematology (CRTH) program kicked off its first workshop of 2026 in Madrid, bringing together 20 early-career hematologists who are ready to challenge assumptions, refine their research questions, and build the foundations of impactful clinical trials.
From project presentations to discussions on research design, ethics, patient involvement, and clinician–statistician collaboration, these sessions have reinforced how much we gain when we learn, question, and support each other. When we approach challenges together, we accelerate progress for patients everywhere - a testament to what coordinated, thoughtful training can achieve through shared purpose.
Find out more about CRTH: eha.fyi/CRTH2026
#CRTH #HematologyEducation #EarlyCareerResearchers #ClinicalResearch
Aisling Barrett retweeted
So sorry to say goodbye to the incredible @ABarrettHaem. We have loved having her in Oxford for 3y. Amazing academic & clinical work, incredible patient care and an all round wonderful colleague. However our loss is Ireland’s gain. All the very best Aisling! @tobyeyre82
As a graduate of this post I couldn’t recommend it more, to those looking for world-class training in clinical trialism and myriad opportunities for research!
Looking for a job which trains you in early phase clinical trials in lymphoid malignancies?
Look no further!
The Oxford early phase clinical trials unit is advertising for a fellow. See link and if you're thinking of applying do get in touch.
ouh.nhs.uk/working-for-us/jo…
Got my hands on a copy of the new edition of the Oxford Handbook of Oncology today, the haematology chapter of which it was a pleasure to update!
Thanks for the opportunity @becshakir
